KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to $347.6 million.

  • CRISPR Therapeutics AG's Cash & Equivalents rose 1652.7% to $347.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $347.6 million, marking a year-over-year increase of 1652.7%. This contributed to the annual value of $347.6 million for FY2025, which is 1652.7% up from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported Cash & Equivalents of $347.6 million as of Q4 2025, which was up 1652.7% from $286.5 million recorded in Q3 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Cash & Equivalents registered a high of $1.6 billion during Q2 2021, and its lowest value of $193.6 million during Q2 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's median Cash & Equivalents value was $464.6 million (recorded in 2023), while the average stood at $554.0 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 7704.46% in 2022, then skyrocketed by 10540.44% in 2024.
  • CRISPR Therapeutics AG's Cash & Equivalents (Quarter) stood at $923.0 million in 2021, then crashed by 77.04% to $211.9 million in 2022, then surged by 83.82% to $389.5 million in 2023, then decreased by 23.41% to $298.3 million in 2024, then rose by 16.53% to $347.6 million in 2025.
  • Its last three reported values are $347.6 million in Q4 2025, $286.5 million for Q3 2025, and $193.6 million during Q2 2025.